Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetes.
Quick Facts
What This Study Found
Orforglipron, an oral non-peptide GLP-1 agonist, improved beta cell function markers by up to 132% and insulin sensitivity in type 2 diabetes patients, with effects exceeding those of injectable dulaglutide.
Key Numbers
378 participants. HOMA-B increased up to 123% (C-peptide) and 132% (insulin) at doses of 12 mg and higher by week 4. HOMA-IR decreased up to 16-23% by week 26. Greater HOMA-B increases than dulaglutide 1.5 mg. Proinsulin/insulin ratio improved. 26-week study.
How They Did This
Exploratory analysis of a 26-week phase 2 RCT. Orforglipron 3, 12, 24, 36, or 45 mg daily vs. dulaglutide 1.5 mg weekly vs. placebo. Beta cell function and insulin sensitivity biomarkers assessed.
Why This Research Matters
Orforglipron could make GLP-1 therapy accessible as a daily pill rather than an injection. It not only controls blood sugar but appears to improve the underlying pancreatic and metabolic dysfunction driving type 2 diabetes.
What This Study Doesn't Tell Us
Exploratory post-hoc analysis. Phase 2, not powered for beta cell endpoints. 26-week duration. Cannot determine if beta cell improvements are sustained long-term. Dulaglutide comparison at only one dose.
Trust & Context
- Original Title:
- Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetes.
- Published In:
- Diabetes, obesity & metabolism, 27(11), 6314-6322 (2025)
- Authors:
- Rosenstock, Julio(10), Robins, Deborah A, Duffin, Kevin L(5), Wilson, Jonathan M, Lin, Yanzhu, Banerjee, Hiya, Eyde, Sarah, Kazda, Christof, Konig, Manige, Mather, Kieren J
- Database ID:
- RPEP-13311
Evidence Hierarchy
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13311APA
Rosenstock, Julio; Robins, Deborah A; Duffin, Kevin L; Wilson, Jonathan M; Lin, Yanzhu; Banerjee, Hiya; Eyde, Sarah; Kazda, Christof; Konig, Manige; Mather, Kieren J. (2025). Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetes.. Diabetes, obesity & metabolism, 27(11), 6314-6322. https://doi.org/10.1111/dom.70022
MLA
Rosenstock, Julio, et al. "Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetes.." Diabetes, 2025. https://doi.org/10.1111/dom.70022
RethinkPeptides
RethinkPeptides Research Database. "Orforglipron, an oral non-peptide glucagon-like peptide-1 re..." RPEP-13311. Retrieved from https://rethinkpeptides.com/research/rosenstock-2025-orforglipron-an-oral-nonpeptide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.